April 29, 2024Open Access

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

Key Points

Key points are not available for this paper at this time.

Abstract

Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Adigweme et al. (Mon,) studied this question.

synapsesocial.com/papers/68e6d04db6db64358764da5b https://doi.org/https://doi.org/10.1016/s0140-6736(24)00532-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Addressing the persistent inequities in immunization coverage2019 · 92 citations
2Impact of measles supplementary immunisation activities on utilisation of maternal and child health services in low-income and middle-income countries2018 · 9 citations
3Measles vaccines: WHO position paper – April 2017.2017 · 252 citations
4The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial2017 · 424 citations
5Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy2014 · 100 citations

Bookmark

View Full Paper